NCT04274283 Tessa Jowell BRAIN MATRIX - Platform Study
| NCT ID | NCT04274283 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Birmingham |
| Condition | Glioma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2020-11-24 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2020-11-24 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis. A large network of clinical hubs across the United Kingdom, with expertise in managing patients with brain tumours, will be developed. Once established this infrastructure will facilitate the rapid introduction of clinical trials testing targeted therapies tailored to the genetic changes of an individual's tumour.
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a tumour sample matched to a blood sample. * Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis). * Valid written informed consent for the study. Exclusion Criteria: * Primary spinal cord tumours * Active treatment of other malignancy * Contraindication to MRI * Patients without standard of care imaging available
Contact & Investigator
Colin Watts
PRINCIPAL INVESTIGATOR
Unviersity of Birmingham
Frequently Asked Questions
Who can join the NCT04274283 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Glioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04274283 currently recruiting?
Yes, NCT04274283 is actively recruiting participants. Contact the research team at brainmatrix@trials.bham.ac.uk for enrollment information.
Where is the NCT04274283 trial being conducted?
This trial is being conducted at Birmingham, United Kingdom, Cambridge, United Kingdom, Cardiff, United Kingdom, Edinburgh, United Kingdom and 10 additional locations.
Who is sponsoring the NCT04274283 clinical trial?
NCT04274283 is sponsored by University of Birmingham. The principal investigator is Colin Watts at Unviersity of Birmingham. The trial plans to enroll 1,000 participants.